Media - Abzena


Manufacturing Capabilities Brochure

From Cell Line Development to Commercial Manufacturing



Immunogenicity and Bioassay Summit

23 October 2017

Following 8 successful years, the Immunogenicity and Bioassay Summit is expanding to include SIX short courses, TWO[...] Read more

European Antibody Congress

31 October 2017

Antibody-based therapies have become established over the past 20 years, and has become one of the most important and[...] Read more


Propagating a Full Spectrum of Services for ADC Development and Manufacture

Download the article in full here The development and manufacture of antibody-drug conjugates (ADCs) requires expertise[...] Read more


Abzena begins the installation of a new 500 L bioreactor at its San Diego facility

Abzena have begun the installation of a new 500L BIOSTAT® STR, single-use bioreactor, as part of a series of significant[...] Read more

Abzena appoints Lotta Ljungqvist as Non-Executive Director

Cambridge, UK, 19 September 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life[...] Read more


We’re changing the way we brand our businesses

To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP,[...] Read more

Interested in our services? Get In Touch